Independent analyst Kunal Bothra has a buy call on Aurobindo Pharma Ltd. with a target price of Rs 650. The current market price of Aurobindo Pharma Ltd. is Rs 612.5 Time period given by the analyst is Intra Day when Aurobindo Pharma Ltd. price can reach the defined target. Kunal Bothra recommended to keep stoploss at Rs 598. Aurobindo Pharma Ltd., incorporated in 1986, is a largecap company with a market cap of Rs 35886.84 crore.
Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 9532.19 Crore to Sales Value (97.45 % of Total Sales), Export Incentives which contributed Rs 233.20 Crore to Sales Value (2.38 % of Total Sales), Scrap which contributed Rs 8.65 Crore to Sales Value (0.08 % of Total Sales) and Sale of services which contributed Rs 7.17 Crore to Sales Value (0.07 % of Total Sales)for the year ending 31-Mar-2017.
For the quarter ended 31-03-2018, the company has reported a Consolidated sales of Rs 3988.63 Crore, down -6.57 % from last quarter Sales of Rs 4268.99 Crore and up 11.35 % from last year same quarter Sales of Rs 3582.13 Crore Company has reported net profit after tax of Rs 528.20 Crore in latest quarter. The companys top management includes Dr.M Sivakumaran, Dr.(Mrs.)Avnit Bimal Singh, Mr.K Nithyananda Reddy, Mr.K Ragunathan, Mr.M Madan Mohan Reddy, Mr.M Sitarama Murthy, Mr.N Govindarajan, Mr.P Sarath Chandra Reddy, Mr.P V Ramprasad Reddy, Mrs.Savita Mahajan. Company has BSR & Associates LLP as its auditoRs As on 30-06-2018, the company has a total of 585,907,609 shares outstanding.